Gains in Colorectal Cancer Outcomes Slowing, Reversing
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 16, 2023 -- Decreases in colorectal cancer (CRC) diagnoses and deaths among adults in their 50s and 60s have slowed compared with previous decades, according to a study recently published in Clinical Gastroenterology and Hepatology.
Caitlin C. Murphy, Ph.D., M.P.H., from University of Texas Health Science Center at Houston, and colleagues used the National Cancer Institute Surveillance, Epidemiology, and End Results data to analyze temporal trends in CRC incidence and mortality by five-year age group (age 30 to ≥85 years), as well as trends in relative survival, during a 28-year period (1992 to 2019).
The researchers found that incidence rates initially decreased for persons aged 60 to 64 years to age 70 to 74 years, but starting in approximately 2011, rates plateaued or decreased more gradually. However, incidence rates consistently increased from age 30 to 34 years to age 50 to 54 years. Some differences were seen for non-White race and ethnicity. There were large declines in mortality observed through the mid-2000s, but then rates began to decrease more gradually for ages 55 to 59 years to 65 to 69 years. Mortality patterns differed by race and ethnicity. Five-year relative survival increased annually by 0.55 percent from 1992 to 2005 across all age groups but thereafter remained unchanged (annual percentage change, 0.04).
"Lower participation in CRC screening among adults in their 50s and 60s may partially explain our findings," the authors write.
One author disclosed ties to the pharmaceutical and health technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.